Found 544 hits.
| 245(a) | Zazzali, J. L., Kaplan, A., Maurer, M. Raimundo, K., Trzaskoma, B., Antonova, E.+ N., and Rosén, K. E.: Comment on “Importance of angioedema-free days in patients with chronic idiopathic or spontaneous urticaria”. Ann. Allergy Asthma Immunol. 2017: 118; 524-526 |
| 85 | Magerl, M., Borzova, E., Giménez-Arnau, A., Grattan, C. E. H., Lawlor, F., Mathelier-Fusade, P., Metz, M., Młynek, A., and Maurer, M.+: The definition and diagnostic testing of physical and cholinergic urticarias – EAACI/GA²LEN/EDF/UNEV consensus panel recommendations. Allergy 2009: 64; 1715-1721. IF: 6.38 |
o.085
| 46. | Mrabet-Dahbi, S. and Maurer, M.: Does allergy impair innate immunity? Leads and lessons from atopic dermatitis. Allergy 2010: 65; 1351-1356. IF: 6.29 |
| 92 | Dudeck, A.+, Leist, M., Rubant, S., Zimmermann, A., Dudeck, J., Boehncke, W. H. and Maurer, M.: Immature mast cells exhibit rolling and adhesion to endothelial cells and subsequent diapedesis triggered by E- and P-selectin, VCAM-1 and PECAM-1. Exp. Dermatol. 2010: 19; 424-434. IF: 4.15 |
| 99 | Braido, F.+, Bousquet, P. J., Brzoza, Z., Canonica, G. W., Compalati, E., Fiocchi, A., Fokkens, W., Gerth van Wijk, R., La Grutta, S., Lombardi, C., Maurer, M. Pinto, A. M., Ridolo, E., Senna, G. E., Terreehorst, I., Todo Bom, A., Bousquet, J., Zuberbier, T., and Baiardini, I.: Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA²LEN taskforce position paper. Allergy 2010: 65; 959-968. IF: 6.29 |
o.099
| 117. | Kocatürk, E., Maurer, M., Metz, M., and Grattan, C.: Looking forward to new targeted treatments for chronic spontaneous urticaria. Clin. Transl. Allergy 2017: 7; 1-10. IF: 3.54
Kocatürk, E., Maurer, M., Metz, M., and Grattan, C.: Erratum to: Looking forward to new targeted treatments for chronic spontaneous urticaria. Clin. Transl. Allergy 2017: 7; 11 |
r.117 r.117a
| 293 | Terhorst, D., Koti, I., Krause, K., Metz, M., and Maurer, M.+: In chronic spontaneous urticaria, high numbers of dermal endothelial cells, but not mast cells, are linked to recurrent angioedema. Clin. Exp. Dermatol. 2018: 43; 131-136. IF: 1.77 |
| 323 | Aygören-Pürsün, E.*+, Bygum, A.*, Grivcheva-Panovska, V., Magerl, M., Graff, J., Steiner, U., Fain, O., Huissoon, A., Kinaciyan, T., Farkas, H., Lleonart, R., Longurst, H., Rae, W., Triggiani, M., Aberer, W., Cancian, M., Zanichelli, A., Smith, W. B., Baeza, M. L., Du-Thanh, A., Gompels, M., Gonzalez-Quevedo, T., Greve, J., Guilarte, M., Katelaris, C., Dobo, S., Cornpropst, M., Clemons, D., Fang, Lei, Collis, P., Sheridan, W., Maurer, M.*, Cicardi, M.*: Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New Engl. J. Med. 2018: 379; 352-362. IF: 70.67 |
| 252 | Krull, C., Schoepke, N., Ohanyan, T., Brachaczek, M., Maurer, M. Lange-Asschenfeldt, B.*, and Metz, M.*+: Increased angiogenesis and VEGF expression correlates with disease severity in prurigo patients. J. Eur. Acad. Dermatol. Venereol. 2016: 30; 1357-1361. IF: 3.52 |
| 401. | Maurer, M.+, Giménez-Arnau, A., Ensina, L. F., Chu, C.-Y., Jaumont, X, and Tassinari, P.: Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results. World Allergy Organ. J. 2020: 13; 100460. IF: 4.08 |
o.401